Patent intelligence · US
US 8202538
Orally disintegrating layered compositions
Orally disintegrating layered compositions
Patent details — US 8202538
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 19, 2012
- Expiration
- Jun 14, 2032
- Applicant
- Capricorn Pharma Inc.
- Claims
- 27
- CPC classes
- A61K, A61K9/0056, A61K9/2086
Quick answer
US 8202538 (Orally disintegrating layered compositions) is held by Capricorn Pharma Inc.. Status: granted. Granted Jun 19, 2012. Expires Jun 14, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Capricorn Pharma Inc.
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61K, A61K9/0056, A61K9/2086
More from Capricorn Pharma Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11801268
Methods of treating ocular inflammation and chemical injuries of the eye with extracellular vesicles
granted -
US 11759482
Methods and compositions for treating skeletal muscular dystrophy
granted -
US 10695293
Method of preventing or treating radiation-induced dermatitis with extracellular vesicles
granted -
US 10369173
Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
granted -
US 9884076
Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
granted -
US 9623085
Chimeric natriuretic peptide compositions and methods of preparation
granted -
US 9616107
Therapy for kidney disease and/or heart failure
granted -
US 9314507
Methods of treatment of heart failure with natriuretic peptides
granted
Frequently asked questions
What is US patent 8202538?
US 8202538 (Orally disintegrating layered compositions) is held by Capricorn Pharma Inc.. Status: granted. Granted Jun 19, 2012. Expires Jun 14, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8202538?
Capricorn Pharma Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 43 pharmaceutical patents for this assignee.
When does US 8202538 expire?
Our index shows an expiration date of Jun 14, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.